Phase III EURO-SKI: Cessation of TKI Therapy Safe, Feasible for Pts Who Achieve Deep Molecular Response

December 3-6, 2016; San Diego, California
Factors associated with MRFS after TKI cessation included longer durations of imatinib therapy, MR4, and pretreatment IFN.
Format: Microsoft PowerPoint (.ppt)
File Size: 408 KB
Released: December 9, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for ALL

Renier J. Brentjens, MD, PhD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

Frederick L. Locke, MD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on emerging CAR T-cell strategies for myeloma.

Noopur Raje, MD Released: December 3, 2020

Downloadable slides on most current clinical data on frontline therapies for CLL.

Jeremy S. Abramson, MD, MMSc Released: December 3, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue